Clinical research leading to a new standard of care developed for the management of untreated primary CNS lymphoma

Impact: Health impacts


I was site PI and second top UK recruiter for the international multi-centre randomised IELSG32 clinical trial. The results of this trial changed practice globally with the development of a new chemotherapy regimen, MATRix. The study was presented in oral plenary sessions at premier haemato-oncology conferences including 13-ICML, ASH 2016 (selected for best of ASH) and 43rd EMBT and published in Lancet Hematology (2016 and 2017). Following its adoption, we undertook a multicentre retrospective analysis on feasibility and effectiveness of MATRix in Routine Clinical Practice (oral presentation at ASH 2017) and audited our own practice at The Christie. Results confirmed the superiority of MATRix over historical treatment approaches and were used to further improve the delivery and safety of treatment.
Impact date20122017
Category of impactHealth impacts
Impact levelBenefit